BLOODPAC Working Group Publishes on COVID-19 Testing Requirements
BLOODPAC’s Policy and Reimbursement Working Group addressed the challenges of rapidly and efficiently increasing COVID-19 testing of the US population in a recently published work, “The COVID-19 Testing We Need”. The group provides an overview of the three types of COVID-19 testing and the process required to accelerate the return to normal economic activity as soon, and safely, as possible. Policy and Reimbursement Working Group participants include: Bristol-Myers Squibb, Center for Medical Technology Policy Inc., Eli Lilly and Company, Epic Sciences, Foundation Medicine, Inc., Illumina, Lexent Bio, LGC Group, Open Commons Consortium, Sysmex Inostics, Thermo Fisher Scientific, University of Chicago, and University of Southern California
